The Study
Cost‐Effectiveness of Low‐Dose Colchicine Prophylaxis When Starting Allopurinol Using the “Start‐Low Go‐Slow” Approach for Gout: Evidence From a Noninferiority Randomized Double‐Blind Placebo‐Controlled Trial
This study is like a fair test where half the people got colchicine and half got sugar pills, and then they tracked how much money was spent and how healthy people felt. It shows that colchicine didn't save enough money or health to be worth it — but it doesn't prove why that happened, just that it didn't work out well in this group.
Analysis score
Maximum 90 for a randomized controlled trial.
Where the score came from
When people start taking allopurinol for gout, they often get flares—so doctors give them colchicine to prevent them. This study checked if that helps enough to justify the extra cost.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 565 / 100
Quality score
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Even though colchicine is cheap, the extra doctor visits and hospital trips after stopping it made it more expensive overall—and didn’t help people feel better long-term.
- 2Colchicine reduced flares for the first 6 months, but after stopping it, flares came back worse—so over 12 months, total flares were the same as placebo.
- 3It cost $2,282 more per person with no extra health benefits.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Arthritis Care & Research
Year
2025
Authors
Yana Pryymachenko, Ross A. Wilson, Nicola Dalbeth, J. Abbott, L. Stamp
Related Content
Claims (6)
Starting allopurinol at a low dose along with anti-inflammatory medication lowers the chance of acute gout flares when lowering uric acid levels.
Adding low-dose colchicine to allopurinol treatment for six months in adults with gout increases health system costs by $2,282 on average over 12 months and does not improve quality-adjusted life years, because gout flares return after stopping colchicine and adherence to allopurinol does not change.
Taking low-dose colchicine for six months while starting allopurinol for gout results in $2,282 higher healthcare costs per patient than taking a placebo, because patients use more healthcare services after stopping colchicine, even though the drug itself is cheap.
Six months of low-dose colchicine taken when starting allopurinol is cost-effective only if the drug is very cheap, such as 6 cents per tablet, but becomes clearly not cost-effective if the drug costs over $5 per tablet.
In adults with gout, stopping low-dose colchicine after six months causes more gout flares than continuing placebo, and over 12 months, the total health benefit measured in quality-adjusted life years is the same as if no colchicine had been taken.
For adults starting allopurinol to treat gout with a gradual dosing approach, taking colchicine for six months does not change how consistently they take allopurinol or lower their blood urate levels compared to taking a placebo.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.